home / lobbying / lobbying_activities

lobbying_activities: 2179531

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2179531 4d93e9e1-902b-4f97-980a-bdd5312e3704 Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2018 third_quarter PHA S. 2553 - Know the Lowest Price Act of 2018- Support of the elimination of "gag clauses" in Medicare Part D. S. 2554 - Patient Right to Know Act - Support of the elimination of "gag clauses" in private market drug benefits. H.R. 6 - Support for Patients and Communities Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 3120 - Helping to End Addition and Lessen Substance Use Disorders Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 2460/H.R. 3528 - Every Prescription Conveyed Securely Act - support for a bill that would require electronic prescribing for opioids. CMS regulations related to the Medicare Part D program and role of Prescription Drug Plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. The Trump Administration's Blueprint for Controlling Prescription Drug Prices - Issues related to the role PBMs can play in controlling the price of prescription medications in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-02T15:21:15.300000-04:00
Powered by Datasette · Queries took 54.863ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API